These results suggest that SGLT2 inhibitors may prevent the development of heart failure via CRS as a result of ameliorating abnormal glucose metabolism in the proximal tubules of the kidney and suppresses OPN production [162]. This evidence concerns the gene SPP1 and heart failure.